General Information of the Drug (ID: M6APDG04237)
Name
MRG-201
Status
Phase 2
TTD Drug ID
D08WZQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
microRNA hsa-miR-155 (MIR155)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary microRNA hsa-miR-155 (MIR155) is a therapeutic target for MRG-201. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MRG-201 through regulating the expression of microRNA hsa-miR-155 (MIR155). [1], [2]
References
Ref 1 MiR-155 regulates m(6)A level and cell progression by targeting FTO in clear cell renal cell carcinoma. Cell Signal. 2022 Mar;91:110217. doi: 10.1016/j.cellsig.2021.110217. Epub 2021 Dec 16.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)